Evidence map›Paper›PMID 32347987›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020

A method to specifically activate the Klotho promoter by using zinc finger proteins constructed from modular building blocks and from naturally engineered Egr1 transcription factor backbone.

Ci-Di Chen, Melissa A Rudy, Ella Zeldich, Carmela R Abraham

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ci-Di ChenKlogene Therapeutics, Inc, Boston, MA, USA.
Melissa A RudyKlogene Therapeutics, Inc, Boston, MA, USA.
Ella ZeldichKlogene Therapeutics, Inc, Boston, MA, USA.
Carmela R AbrahamKlogene Therapeutics, Inc, Boston, MA, USA.
Klogene (United States) · US

Funding

A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMER’S DISEASER44AG053084 · NIA · KLOGENE THERAPEUTICS, INC. · PI ABRAHAM, CARMELA, ABRAHAM, MENACHEM · 2016 to 2017
$1.5M
NIA NIH HHS R44 AG053084
6 · The paper itself

Abstract

There is an unmet need for treatments for diseases associated with aging. The antiaging, life-extending, and cognition-enhancing protein Klotho is neuroprotective due to its anti-inflammatory, antioxidative, and pro-myelinating effects. In addition, Klotho is also a tumor suppressor and has beneficial roles in multiple organs. Klotho is downregulated as part of the aging process. Thus, upregulating Klotho in the brain may lead to novel therapeutics to people suffering or at risk for neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, and demyelinating diseases such as multiple sclerosis. We attempted to upregulate Klotho for its beneficial effects in the brain and elsewhere. Here, we describe a method to specifically activate Klotho gene expression. To accomplish this task, we designed zinc finger proteins (ZFPs) targeting within -300 bps of the human Klotho promoter. We designed the ZPF constructs either de novo from modular building blocks, or modified sequences from the natural endogenous Egr1 transcription factor backbone structure. Egr1 is known to upregulate Klotho expression. We tested the transcriptional activation effects of these ZFPs in a dual luciferase coincidence reporter system under the control of 4-kb promoter of human Klotho in stable HEK293 cells and in HK-2 cells that express Klotho protein endogenously. We found that the best ZFPs are the de novo designed ones targeting -250 bps of Klotho promoter and one of the Egr1-binding sites. We further enhanced Klotho's activation using p65-Rta transcriptional activation domains in addition to VP64. These upregulation approaches could be useful for studying Klotho's protective effects and designing Klotho boosting therapeutics for future in vivo experiments.

Indexed as

AgingBinding SitesBrainCell LineCognitionEarly Growth Response Protein 1Gene ExpressionGlucuronidaseHEK293 CellsHumansKlotho ProteinsLuciferasesNeurodegenerative DiseasesPromoter Regions, GeneticTranscriptional ActivationUp-RegulationEarly Growth Response Protein 1EGR1 protein, humanGlucuronidaseKlotho ProteinsLuciferasesagingAlzheimer's diseasecancerkidney diseaseneurodegenerationtranscription factor

Identifiers

PMID32347987
PMCPMC7302970
OpenAlexW3020708175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.